Evaluation of genetic melanoma vaccines in cdk4‐mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin

We evaluated the efficacy of a candidate melanoma vaccine approach in mice genetically prone to develop melanoma due to the introduction of an oncogenic mutation (R24C) in the germline sequence of the cyclin‐dependent kinase 4 (cdk4), a protein critically involved in cell cycle regulation. Melanomas were induced in cdk4‐mutant mice by chemical carcinogenesis and UVB irradiation. A genetic prime‐boost strategy targeting the clinically relevant differentiation antigen tyrosinase‐related protein 2 (TRP2) was performed which was able to stimulate a melanocyte‐specific cellular immune response associated with localized autoimmune vitiligo‐like depigmentation. However, significant destruction of carcinogen‐induced autochthonous melanocytic neoplasms in the skin was not observed following immunization. We provide evidence that autochthonous melanomas expressed TRP2 but not the MHC molecule H2‐Kb and are immunologically tolerated in the skin. Our results highlight the importance of assessing melanoma vaccines in genetic mouse models that more adequately represent the expected clinical situation in order to identify strategies, which eventually may be of benefit for melanoma patients. © 2005 Wiley‐Liss, Inc.

[1]  T. Bieber,et al.  Enhanced type I interferon signalling promotes Th1‐biased inflammation in cutaneous lupus erythematosus , 2005, The Journal of pathology.

[2]  T. Tüting,et al.  Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. , 2005, The Journal of investigative dermatology.

[3]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[4]  J. Bramson,et al.  Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin , 2004, Cancer Research.

[5]  L. Rénia,et al.  Spontaneous Vitiligo in an Animal Model for Human Melanoma , 2004, Cancer Research.

[6]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[8]  G. Hämmerling,et al.  Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. , 2002, Cancer research.

[9]  A. Gambotto,et al.  Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity , 2002, Gene Therapy.

[10]  M. Barbacid,et al.  Invasive melanoma in Cdk4-targeted mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Duray,et al.  Neonatal sunburn and melanoma in mice , 2001, Nature.

[12]  A. Enk,et al.  Genetic immunization of mice with human tyrosinase‐related protein 2: Implications for the immunotherapy of melanoma , 2000, International journal of cancer.

[13]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[14]  M. Barbacid,et al.  Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia , 1999, Nature Genetics.

[15]  M. Lotze,et al.  Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice , 1999, Cancer Gene Therapy.

[16]  A Sette,et al.  Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). , 1998, Cancer research.

[17]  R. Paus,et al.  MHC class I expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo. , 1998, The Journal of investigative dermatology.

[18]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[19]  S. Rosenberg.  Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[20]  N. Kirkham,et al.  AN IMMUNOCYTOCHEMICAL STUDY OF MHC CLASS I EXPRESSION ON HUMAN LANGERHANS CELLS AND MELANOCYTES , 1997, The Journal of pathology.

[21]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[22]  P. van der Bruggen,et al.  T cell defined tumor antigens. , 1997, Current opinion in immunology.

[23]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[24]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[25]  M. Mihm,et al.  Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. , 1982, Journal of immunology.